HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.
about
Human Leukocyte Antigen Diversity: A Southern African PerspectivePoxvirus vectors as HIV/AIDS vaccines in humansHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designHIV-1 vaccines: challenges and new perspectivesNovel directions in HIV-1 vaccines revealed from clinical trialsNonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesUse of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individualsEmerging concepts on T follicular helper cell dynamics in HIV infectionInduction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial.HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases.Recent advances in research of HIV infection: implications of viral and host genetics on treatment and prevention.
P2860
Q26782686-698BA2F4-DE7C-42D7-A736-31A31FECB0BBQ26995078-8A98F2CA-81EA-454E-AF0D-886EAC948364Q27022055-75761993-898A-400F-BA3F-A4CFE333703CQ33577972-BF7BC85F-C65A-4B00-BE15-1ABF60E299E3Q33645528-05B52723-12C8-4C46-BF1E-7D6CC4F5CF3CQ34057711-13192EF4-A4AB-4FAE-99ED-7B53D4C817CFQ34630184-BA6F7D52-5738-4080-8F0E-CD98FD7E3711Q34687653-2B6286A6-0918-4323-9C57-80113B8D21F0Q34980976-BE26B8A4-C4C6-4C57-9F5E-7DF5CE554752Q36003331-2358699E-CC85-4548-9C0B-5517094FD991Q37013490-86BDF041-0F00-461E-B9BA-321322C5CF6DQ37607358-3C69B13E-BA08-4B53-8D9F-0675495D58EDQ38075857-2AAB4070-B92B-4B15-9C1B-17E23F70C6ADQ38095239-D908DFE0-989E-4C10-B3A0-7FBBCCE5A2EE
P2860
HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/E.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
HLA class II restriction of HI ...... ation of ALVAC-HIV and AIDSVAX
@nl
HLA class II restriction of HI ...... ALVAC-HIV and AIDSVAX(®) B/E.
@en
type
label
HLA class II restriction of HI ...... ation of ALVAC-HIV and AIDSVAX
@nl
HLA class II restriction of HI ...... ALVAC-HIV and AIDSVAX(®) B/E.
@en
prefLabel
HLA class II restriction of HI ...... ation of ALVAC-HIV and AIDSVAX
@nl
HLA class II restriction of HI ...... ALVAC-HIV and AIDSVAX(®) B/E.
@en
P2093
P1433
P1476
HLA class II restriction of HI ...... ALVAC-HIV and AIDSVAX(®) B/E.
@en
P2093
Anna Sambor
Arthur E Brown
Chitraporn Karnasuta
Donald Francis
Henry A Stephens
Mark S de Souza
Prasert Thongcharoen
Punnee Pitisuttithum
Robert Paris
Sanjay Gurunathan
P304
P356
10.1016/J.VACCINE.2011.11.002
P407
P577
2011-11-12T00:00:00Z